UNSPSC 51343807: Peginterferon/ribavirin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343807 Peginterferon/ribavirin is a Commodity code for antiviral pharmaceutical products, yet recent state and local procurement activity under this code shows minimal direct alignment with the nominal scope. The two most recent opportunities tagged to this code involve unrelated pharmaceuticals — one an Illinois Department of Public Health piggyback contract for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) awarded to Chartwell Rx LLC for $2,999,999.11 over three years, and another a Seminole County, Florida IFB for Naloxone and drug deactivation systems for community health support. State and local governments do source pharmaceutical products through cooperative purchasing vehicles such as MMCAP Infuse and direct IFB processes, but the tagging of non-antiviral medications to a peginterferon/ribavirin code suggests either taxonomy misalignment in the underlying procurement system or minimal actual solicitation activity under this specific commodity code.

The geographic spread evident in recent tagged opportunities spans Illinois and Florida, with issuing bodies including state health departments and county health authorities. However, because the recorded opportunities do not involve the pharmaceutical class named in the code, this summary cannot reliably characterize demand for peginterferon/ribavirin itself or forecast pursuit opportunity at this code level. Firms evaluating this commodity should cross-reference recent Illinois and Florida health department procurement notices and cooperative purchasing consortia catalogs directly rather than rely on the current code tagging, and should confirm whether state Medicaid agencies or corrections departments are actively sourcing this antiviral product through open solicitations.